Aster Capital Management (Difc) LTD Phathom Pharmaceuticals, Inc. Transaction History
Aster Capital Management (Difc) LTD
- $462 Billion
- Q3 2024
A detailed history of Aster Capital Management (Difc) LTD transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Aster Capital Management (Difc) LTD holds 45 shares of PHAT stock, worth $438. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45Holding current value
$438% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
144Shares Held
73.2MCall Options Held
42.3KPut Options Held
45.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$98.6 Million6.14% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$72.8 Million28.04% of portfolio
-
Jennison Associates LLC5.87MShares$57.2 Million0.07% of portfolio
-
Invesco Ltd. Atlanta, GA4.1MShares$39.9 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$34.1 Million9.52% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $382M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...